1[1]Havel RJ. Rgulation of lipoprotein metabolism by lipoprotein receptors[ J].Atheroscler Rev, 1998,17(1): 1 - 8.
2[2]Choi S Y,Fong L G,Kirven M J,et al. Use of an antiLDL receptor antibody to quantify the rol of the LDL receptor in removal of chylomicron - remnant in the mouse in vivo[J] .J Clin Invest, 1996,88(10):1173- 1181.
3[3]Szanto A. Balasubramaniam S. Roach P D. et al. Modulation of LDL receptor related protein and its relevance to chylomicron- remnant metabolism[ J].Biochem J, 1998,46(7) :791 - 794.
4[4]Todd P A.Goa K L. Fluvastatin:A Review of its pharmacological properties and therapeutic potential in hypercholesterolaemia[ J]. Drug, 1990,40(5):583 - 607.
5[5]Evans A J, Huff M W, Wlfe B M. Accumulation of an apoE - poor subfraction of very low density lipoprotein in hypertigly ceridemic men[J]. J Lipid Res, 1999,30( 11 ): 1671 - 1701.
6[6]Reddick R L,Zhang S H,Maeda N. Atherosclerosis in mice lacking apoE.Evaluation of lesion development and progression[ J ]. Arterioscler Thromb,1998,14(2): 141 - 147.
7[7]Saku K J, Zhang b, Ohta, T K, et al. Quantity and function of high density lipoprotein as an indictor of coronary atherosclerosis[ J]. J Am Coll Cardiol,1999,33(8) :340 - 443.
